Lv1
20 积分 2024-11-08 加入
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
25天前
已完结
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
2个月前
已完结
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study
2个月前
已完结
Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial
3个月前
已完结
Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs
3个月前
已完结
Unlocking Natural Potential: Antibody‐Drug Conjugates With Naturally Derived Payloads for Cancer Therapy
3个月前
已完结
Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates
3个月前
已完结
The journey of antibody-drug conjugates for revolutionizing cancer therapy: A review
3个月前
已完结
Utidelone Plus Bevacizumab for ERBB2-Negative Metastatic Breast Cancer and Active Brain Metastases
3个月前
已完结
Nasopharyngeal carcinoma
3个月前
已完结
皖公网安备34019202002308
